Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications
Sign Up to like & getrecommendations! Published in 2021 at "ESMO Open"
DOI: 10.1016/j.esmoop.2021.100072
Abstract: Background Entrectinib is a tropomyosin receptor kinase inhibitor approved for the treatment of neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours based on single-arm trials. Traditional randomised clinical trials in rare cancers are not feasible;… read more here.
Keywords: entrectinib; analysis; prior therapy; single arm ... See more keywords
Efficacy of selpercatinib after prior systemic therapy in patients with RET mutant medullary thyroid cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.6074
Abstract: 6074 Background: Selpercatinib is a first-in-class, CNS active, highly selective, and potent RET kinase inhibitor which has demonstrated durable antitumor activity in patients (pts) with RET altered thyroid cancer and is approved in multiple countries… read more here.
Keywords: therapy; response; thyroid cancer; prior therapy ... See more keywords
Downregulation of Tumour Necrosis Factor α Gene Expression in Peripheral Blood Mononuclear Cells Cultured in the Presence of Tofacitinib Prior to Therapy Is Associated with Clinical Remission in Patients with Rheumatoid Arthritis
Sign Up to like & getrecommendations! Published in 2022 at "Current Issues in Molecular Biology"
DOI: 10.3390/cimb44050132
Abstract: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by pain, synovial hyperplasia, mononuclear cell infiltration, bone erosion and joint destruction. Efficacy of personalized therapy in RA is associated with correct choice of therapeutic agent… read more here.
Keywords: prior therapy; remission; therapy; expression ... See more keywords